Trial Profile
Phase 4 Study of Ranibizumab for the Treatment of Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Initial Fair Visual Acuity
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Branch retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- 18 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 13 Nov 2017 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
- 13 Nov 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2017.